Clinical Trial Update: New Non-invasive Biomarkers of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)

View source ↗

Summary

This document provides an update on the development of new non-invasive biomarkers for metabolic dysfunction-associated steatotic liver disease (MASLD) and its …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Metabolic Dysfunction-associated Steatohepatitis
• Metabolic Dysfunction-associated Steatotic Liver Disease
• Nonalcoholic Fatty Liver Disease

Snippet

Sponsor: General University Hospital, Prague | Conditions: Healthy, Simple Steatosis (SS) | Status: COMPLETED